Lactoferrin for Iron Deficiency Anemia

Verdict: Promising but unconfirmed; not standard care

Several small trials suggest oral lactoferrin can raise hemoglobin in iron-deficiency anemia at least as well as ferrous iron, often with fewer digestive side effects. But the evidence is preliminary and no health regulator or clinical guideline endorses it as a treatment, so it is not a substitute for standard iron therapy.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The clinical signal is consistent but thin. Two meta-analyses and a systematic review (PMID 29059584; PMID 35276902; PMID 37661669) all found oral lactoferrin matched or beat ferrous salts on hemoglobin, with a pooled rise of about 0.77 g/dL in pregnancy and 1.18 g/dL in a broader pooled analysis, alongside fewer gastrointestinal complaints. A small hemodialysis RCT (PMID 38231718) and a mechanistic review (PMID 34440102) point to an anti-inflammatory, hepcidin-lowering pathway. The direction is reassuringly uniform.

What holds this back from a higher grade is the lack of independent confirmation. The pivotal pregnancy trials come largely from a single Egyptian research group, the largest RCT enrolled only 140 patients, doses and lactoferrin formulations vary widely, and funding is often undisclosed. There is no large, multi-center Phase III trial of the kind that underpins standard iron salts.

Institutional backing is essentially absent. Regulators approve lactoferrin only as a food ingredient (US FDA: "FDA has no questions"; EFSA as a safe novel food; Taiwan TFDA as nutritional additive), with no approved disease claim. Major clinical sources, including NIH ODS, Mayo Clinic, Cleveland Clinic, Harvard Health and the ASH/AGA guidelines, do not mention it for this condition. Oral or IV iron remains first-line, and IDA should be diagnosed and its underlying cause investigated before any supplement is considered.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.625
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials
PMID: 29059584 2017 統合分析 n = 600
Finding: Pooled estimates favored lactoferrin over ferrous sulfate for hemoglobin rise at 4 weeks (MD 0.77 g/dL, 95% CI 0.04–1.55, p=0.04). Subgroup: moderate anemia favored lactoferrin (MD 0.68 g/dL, 95% CI 0.53–0.83, p<0.00001); mild anemia showed no significant difference. Significantly fewer GI side effects with lactoferrin.
Effect size: MD Hb +0.77 g/dL overall; +0.68 g/dL moderate anemia subgroup
View on PubMed
Comparative Effects between Oral Lactoferrin and Ferrous Sulfate Supplementation on Iron-Deficiency Anemia: A Comprehensive Review and Meta-Analysis of Clinical Trials
PMID: 35276902 2022 統合分析
Finding: Lactoferrin superior to ferrous sulfate on hemoglobin (MD 11.80 g/L, p<0.00001), serum iron (MD 41.44 μg/dL, p<0.00001) and ferritin (MD 13.60 ng/mL, p=0.003). Lactoferrin reduced IL-6 (MD −45.59 pg/mL, p<0.00001), suggesting anti-inflammatory mechanism via hepcidin downregulation.
Government Effect size: MD Hb +11.80 g/L (~1.18 g/dL) favoring lactoferrin
View on PubMed
Lactoferrin as treatment for iron-deficiency anemia in children: a systematic review
PMID: 37661669 2023 系統性回顧
Finding: Serum ferritin and hemoglobin increased in lactoferrin or lactoferrin+iron groups vs iron only or placebo. Significant reduction in constipation with lactoferrin; other GI events (vomiting, anorexia, abdominal pain) still observed. Authors concluded lactoferrin a superior treatment for pediatric IDA on both efficacy and adverse-event profile.
Effect size: Direction favors lactoferrin (narrative; pooled estimates not extracted in abstract)
View on PubMed
Lactoferrin: A Promising New Player in Treatment of Iron Deficiency Anemia in Patients on Regular Hemodialysis: A Randomized Controlled Trial
PMID: 38231718 2023 隨機對照試驗 n = 140
Finding: Hemoglobin rose from 7.5–8.1 g/dL to 9.3–10 g/dL in lactoferrin group vs 7.5–8.1 to 7.6–8.5 g/dL in ferrous glycine sulfate group; lactoferrin reduced hepcidin and improved iron markers more than control. Lactoferrin positioned as a promising novel agent for IDA in hemodialysis patients.
Effect size: Hb gain ~+1.8 g/dL (lactoferrin) vs ~+0.1–0.4 g/dL (control)
View on PubMed
Lactoferrin for Prevention and Treatment of Anemia and Inflammation in Pregnant Women: A Comprehensive Review
PMID: 34440102 2021 Other
Finding: Oral lactoferrin normalizes iron homeostasis by facilitating absorption and inhibiting inflammatory processes (suppression of pro-inflammatory cytokines and hepcidin). BLTF described as GRAS-recognized, with multidirectional benefits beyond iron supply. Supports lactoferrin as a viable alternative to ferrous salts for pregnancy IDA.
Effect size: Qualitative; mechanism-supportive
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions source↗
L4b EU EFSA
Supportive
L4d TW TFDA / 衛福部
Supportive
第(八)類 營養添加劑 編號08112 乳鐵蛋白 — 自中華民國一百十二年一月一日施行 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-iron-deficiency-anemia-INT-lactoferrin-001 繁體中文版 →